Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is approximately 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The current consensus among eleven TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price target of eighty four dolars.
The analysts price targets range from a high of hundred one dolars to a low of $61.
In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment has offering of prescribed drugs and assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in providing administrative services as well as management. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.